Laboratory of Lymphocyte Signaling and Oncoproteome

Legal notice

Legal Disclosure

Information in accordance with Section 5 TMG 

Kerpener Str. 62
Haus 15, Raum. 1.010
50937 Köln

Represented by

Marco Herling

Contact Information

Telephone: +49 (0) 221 478 5969
E-Mail: petra.mayer@uk-koeln.de
Internet address: herlinglab.com

Verantwortlich für den Inhalt dieser Seiten:

Marco Herling
Kerpener Str. 62, Haus 15, R.1.010
Telefon: +49 (0) 221 478 5969
E-Mail: petra.mayer@uk-koeln.de
Internet: herlinglab.com

News

Future therapies in T-PLL and T-LGL

Future therapies in T-PLL and T-LGL

June 7, 2021

New perspective on future targeted therapy approaches published.

New article accepted for publication

New article accepted for publication

August 30, 2020

Our work on T-PLL cells resembling the phenotype of activated memory-type effector T-cells has been accepted in Blood

Alkylating deacetylase inhibitor tinostamustine in T-PLL

March 11, 2020

New letter evaluating the effects of EDO-S101/tinostamustine published in Leukemia.

Advances and Perspectives in the Treatment of T-PLL

Advances and Perspectives in the Treatment of T-PLL

February 25, 2020

New review on current and future strategies in treating T-PLL published in Current Hematologic Malignancy Reports